RARA and neoplasm: In summary, our study has identified targeting the NCoR1/RARα interaction as a feasible and effective way to selectively downregulate CMA in NSCLC and developed a first-in-class CMA inhibitory small molecule with a unique mechanism of action and in vivo therapeutic efficacy in NSCLC tumor xenografts.